ETDate	Trans No.	ET Req status	Party name		
	20090769	G G	Intuit Inc. Mint Software Inc. Mint Software Inc.		
23-OCT-09	20100025	G G	Clayton, Dubilier & Rice Fund VIII, L.P. Appointive Distributing Trust B u/a Samuel Johnson, 1988 T#1.		
	20100036	G G G	JohnsonDiversey Holdings, Inc. Emerson Electric Co. Avocent Corporation.		
26-OCT-09	20090788	G G	Avocent Corporation. Oak Hill Capital Partners III, L.P. ODN Holding Corporation.		
27-OCT-09	20100022	G G	ODN Holding Corporation.  Macquarie Group Limited.		
	20100024	G G G	Fox-Pitt Kelton Cochran Caronia, Waller LLC Fox-Pitt Kelton Cochran Caronia Waller LLC. GrainCorp Limited. United Malt Holdings LP.		
		G G	Malt U.K. Holdco Limited. Malt Luxco S.a.r.l. Malt U.S. Holdco, Inc.		
28-OCT-09	20100037	G G	Iconix Brand Group, Inc. Seth Gerszberg. Yakira, L.L.C.		
	20100038	G G	Iconix Brand Group, Inc. Marc Ecko.		
	20100041	G G G	Yakira, L.L.C. Macquarie Group Limited. Lincoln National Corporation.		
	20090501	G G G	Delaware Management Holdings, Inc. AOI Bedding Super Holdings, LLC. Thomas H. Lee Equity Fund V, L.P.		
	20090691	G G G	THL-SC Bedding Company. Bayer AG. Athenix Corp.		
	20090792	G G	Athenix Corp. Abbott Laboratories. Evalve, Inc.		
	20100035	G G	Evalve, Inc. ViaSat, Inc.		
29-OCT-09	20090405	G G G G	WildBlue Holding, Inc. WildBlue Holding, Inc. Schering-Plough Corporation. Merck & Co., Inc. Merck & Co., Inc.		

For Further Information Contact: Sandra M. Peay, Contact Representative, or Renee Hallman, Contact Representative, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room H– 303, Washington, DC 20580, (202) 326– 3100.

By Direction of the Commission.

#### Donald S. Clark,

Secretary.

[FR Doc. E9–27413 Filed 11–17–09; 8:45 am]

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **Indian Health Service**

Request for Public Comment: 60-Day Proposed Information Collection: Office of Urban Indian Health Programs Uniform Data System

**AGENCY:** Indian Health Service. **ACTION:** Notice.

SUMMARY: In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 which requires 60 day advance opportunity for public comment on proposed information collection projects, the Indian Health Service (IHS) is publishing for comment a summary of a proposed information collection to be submitted to the Office of Management and Budget (OMB) for review.

Proposed Collection: Title: Office of Urban Indian Health Programs (OUIHP) Uniform Data System (UDS). Type of Information Collection Request: Initial request and four year extension, for data collection to ensure compliance with legislative mandates and report to Congress and policymakers on program accomplishments. Form Number(s): New data collection. There are currently no form numbers. Reporting formats are contained in the UDS Instruction Manual. Need and Use of Information Collection: The Uniform Data System (UDS) contains the annual reporting requirements for the cluster of primary health care and case management/ outreach and referral grantees funded by the IHS. The UDS includes reporting requirements for grantees of the OUIHP. The authorizing statute is Title V of Public Law 94-437, of the Indian Health Care Improvement Act, as amended. IHS will collect data in the UDS which will be used to ensure compliance with the legislative mandates and report to Congress and policymakers on program accomplishments. To meet these objectives, the OUIHP requires a core set of data collected annually that is appropriate for monitoring and evaluating performance and reporting on annual trends. *Affected Public:* Title V funded Urban Indian health programs. *Type of Respondents:* Title V Urban Indian health programs.

The table below provides: Types of data collection instruments, Number of respondents, Response per respondent, Total annual responses, Average burden hour per response, and Total annual burden hours.

Data collection instrument(s)	Number of respondents	Responses per respond- ent	Total annual responses	Average burden hour per response*	Total annual burden hours
Universal Report American Indian/Alaska Native Report.	34 34	1 1		8.00 (480 min) 8.00 (480 min)	272 272
Total	68				544

<sup>\*</sup> For ease of understanding, burden hours are also provided in actual minutes.

There are no Capital Costs, Operating Costs, and/or Maintenance Costs to report.

Request for Comments: Your written comments and/or suggestions are invited on one or more of the following points: (a) Whether the information collection activity is necessary to carry out an agency function; (b) whether the agency processes the information collected in a useful and timely fashion; (c) the accuracy of public burden estimate (the estimated amount of time needed for individual respondents to provide the requested information); (d) whether the methodology and assumptions used to determine the estimate are logical; (e) ways to enhance the quality, utility, and clarity of the information being collected; and (f) ways to minimize the public burden through the use of automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

Send Comments and Requests for Further Information: Send your written comments and requests for more information on the proposed collection or requests to obtain a copy of the data collection instrument(s) and instructions to: Ms. Betty Gould, Reports Clearance Officer, 801 Thompson Avenue, TMP, Suite 450, Rockville, MD 20852; call non-toll free (301) 443–7899; send via facsimile to (301) 443–9879; or send your e-mail requests, comments, and return address to: betty.gould@ihs.gov.

Comment Due Date: Your comments regarding this information collection are best assured of having full effect if received within 60 days of the date of this publication.

Dated: November 10, 2009.

### Yvette Roubideaux,

Director, Indian Health Service. [FR Doc. E9–27540 Filed 11–17–09; 8:45 am] BILLING CODE 4165–16–M

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **Food and Drug Administration**

[Docket No. FDA-2009-N-0291]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Infectious Disease Issues in Xenotransplantation

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

**DATES:** Fax written comments on the collection of information by December 18, 2009.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202–395–6974, or e-mailed to oira\_submission@omb.eop.gov. All comments should be identified with the OMB control number 0910–0456. Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Liz Berbakos, Office of Information Management (HFA-710), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-796-3792, Elizabeth.berbakos@fda.hhs.gov.

**SUPPLEMENTARY INFORMATION:** In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed

collection of information to OMB for review and clearance.

#### Infectious Disease Issues in Xenotransplantation—(OMB Control Number 0910–0456)—Extension

The statutory authority to collect this information is provided under sections 351 and 361 of the Public Health Service (PHS) Act (42 U.S.C. 262 and 264) and the provisions of the Federal Food, Drug, and Cosmetic Act that apply to drugs (21 U.S.C. 301 et seq.). The PHS guideline recommends procedures to diminish the risk of transmission of infectious agents to the xenotransplantation product recipient and to the general public. The PHS guideline is intended to address public health issues raised by xenotransplantation, through identification of general principles of prevention and control of infectious diseases associated with xenotransplantation that may pose a hazard to the public health. The collection of information described in this guideline is intended to provide to sponsors general guidance on the following topics: (1) The development of xenotransplantation clinical protocols, (2) the preparation of submissions to FDA, and (3) the conduct of xenotransplantation clinical trials. Also, the collection of information will help ensure that the sponsor maintains important information in a cross-referenced system that links the relevant records of the xenotransplantation product recipient, xenotransplantation product, source animal(s), animal procurement center, and significant nosocomial exposures. The PHS guideline describes an occupational health service program for the protection of health care workers involved in xenotransplantation procedures, caring for xenotransplantation product recipients,